| Literature DB >> 32420349 |
Giada Lavitola1, Luigi Della Corte1, Nicoletta De Rosa1, Carmine Nappi2, Giuseppe Bifulco1.
Abstract
OBJECTIVE: Evaluate the effects of carboxy-methyl-beta-glucan on cervical epithelialization and on the vaginal microbiota in patients with HPV infection or low-grade cervical preneoplastic lesion (CIN 1).Entities:
Mesh:
Substances:
Year: 2020 PMID: 32420349 PMCID: PMC7201736 DOI: 10.1155/2020/5476389
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The demographic and anamnestic variables of the subjects under study.
| Groupp A ( | Group B ( |
| |
|---|---|---|---|
| Age (year)§ | 34.02 ± 6.5 | 34.2 ± 6.2 | 0.71 |
| Parity (no.)∗ | 1 (0-3) | 1 (0-3) | 0.52 |
| Educational level∗ | 2 (1-3) | 2 (1-3) | 0.64 |
| Smoke° | |||
| ≤10 sig/die | 190 (53.1) | 187 (52.2) | 0.81 |
| >10 sig/die | 168 (46.9) | 171 (47.8) | |
| Alchohol habits° | |||
| Weekly | 301 (84.1) | 318 (86.6) | 0.33 |
| Daily | 57 (15.9) | 49 (13.4) | |
| Sexual partners° | |||
| ≤4 | 94 (26.3) | 112 (30.5) | 0.20 |
| >4 | 264 (73.7) | 255 (69.5) |
° χ square, §t-test, ∗Mann–Whitney.
Figure 1Abnormal transformation zone (ATZ)—CIN 1 before treatment with carboxy-methyl-beta-glucan.
Figure 2Normal transformation zone (NTZ) after treatment with carboxy-methyl-beta-glucan.
Epithelialization and vaginal health indexes in the two study groups.
| Time 0 months |
| Time 6 months |
| Difference % group A | Difference % group B | |||
|---|---|---|---|---|---|---|---|---|
| Group A ( | Group B ( | Group A ( | Group B ( | |||||
| Ectopia | 0.10 | 0.006 | ||||||
| ≤2/3 | 216 (60.3) | 244 (66.5) | 285 (79.6) | 260 (70.8) | ||||
| >2/3 | 142 (39.7) | 123 (39.7) | 73 (20.4) | 107 (29.2) | -48.6% | -13% | ||
| Metaplasia | 0.11 | <0.001 | ||||||
| ≤20% | 275 (76.8) | 263 (71.7) | 180 (50.3) | 248 (67.6) | ||||
| >20% | 83 (23.2) | 104 (28.3) | 178 (49.7) | 119 (32.4) | 114.5% | 14.4% | ||
| Lugol test | 0.97 | <0.001 | ||||||
| Negative | 52 (14.5) | 53 (14.4) | 164 (45.8) | 95 (25.9) | ||||
| Positive | 306 (85.5) | 314 (85.6) | 195 (54.2) | 272 (74.1) | -36.3% | -13.4 | ||
| pH | 0.59 | <0.001 | ||||||
| ≤4.5 | 208 (58.1) | 206 (56.1) | 306 (85.5) | 212 (57.8) | ||||
| >4.5 | 150 (41.9) | 161 (43.9) | 52 (14.5) | 155 (42.2) | -65.3% | -3.7% | ||
| Swift test | 0.41 | <0.001 | ||||||
| Negative | 188 (52.5) | 204 (55.6) | 313 (87.4) | 212 (57.8) | ||||
| Positive | 170 (47.5) | 163 (44.4) | 45 (12.6) | 155 (42.2) | -73.5% | -4.9% | ||
| Leucorrhoea | 0.10 | <0.001 | ||||||
| Absent | 57 (15.9) | 76 (20.7) | 260 (72.6) | 117 (31.9) | ||||
| Present | 301 (84.1) | 291 (79.3) | 98 (27.4) | 250 (68.1) | -67.4% | -14.1% | ||
Figure 3(a) Epithelialization and vaginal health indexes in the two study groups. (b) Epithelialization and vaginal health indexes in the two study groups.
Cytological, molecular, colposcopic, and histological reports in the two study groups.
| Time 0 months |
| Time 6 months |
| Difference % group A | Difference % group B | |||
|---|---|---|---|---|---|---|---|---|
| Group A ( | Group B ( | Group A ( | Group B ( | |||||
| Pap smear | 0.75 | <0.001 | ||||||
| Negative | 67 (18.7) | 72 (19.6) | 175 (48.9) | 117 (31.9) | ||||
| Positive | 291 (81.3) | 295 (80.4) | 183 (51.1) | 250 (68.1) | -37.1% | -15.2% | ||
| HPV test | 0.55 | <0.001 | ||||||
| Negative | 2 (1.3) | 4 (2.2) | 61 (40.7) | 33 (18.3) | ||||
| Positive | 148 (98.7) | 176 (97.8) | 89 (59.3) | 147 (81.7) | -39.9% | -16.5% | ||
| Colposcopy | ||||||||
| Negative | 64 (17.9) | 66 (18.0) | 0.97 | 212 (59.2) | 145 (39.5) | <0.001 | ||
| Positive | 294 (82.1) | 301 (82.0) | 146 (40.8) | 222 (60.5) | -50.3% | -26.2% | ||
| Biopsy | ||||||||
| Negative | 131 (36.6) | 136 (37.1) | 0.89 | 216 (60.3) | 161 (43.9) | <0.001 | ||
| Positive | 227 (63.4) | 231 (62.9) | 142 (39.7) | 206 (56.1) | -37.4% | -10.8% | ||
Figure 4Cytological, molecular, colposcopic, and histological reports in the two study groups.
Relative risk of persistence of injury in relation to the variables under study.
| Case | Total | RR (IC 95%) | |
|---|---|---|---|
| Smoke habits > 10 cig | 216 | 384 | 2.04 (1.51-2.74) |
| Daily alcohol use | 46 | 106 | 0.81 (0.53-1.21) |
| Partner > 4 | 255 | 519 | 1.17 (0.85-1.62) |
| Ectopia > 2/3 | 117 | 180 | 2.52 (1.78-3.58) |
| Metaplasia > 20% | 145 | 297 | 1.06 (0.78-1.42) |
| Lugol test positive | 305 | 466 | 9.52 (6.51-13.90) |
| pH > 4.5 | 126 | 207 | 2.07 (1.49-2.88) |
| Wift test positive | 122 | 200 | 2.07 (1.48-2.89) |
| Presence of leucorrhoea | 222 | 348 | 3.51 (2.58-4.76) |
| Treatment | 142 | 358 | 0.51 (0.38-0.69) |